The world’s first ovarian cancer vaccine has been awarded research funding in the United Kingdom, marking the first step toward a groundbreaking preventive measure that scientists say could eliminate the disease entirely.

OvarianVax is being developed by scientists at the University of Oxford. Cancer Research U.K. awarded the team on Friday with up to $790,000 over the next three years.

Recommended Stories

FDA ‘liberates’ hormone therapy for menopause

Insurance slow to pay for shots

FDA authorizes extra dose of COVID-19 vaccine for immunocompromised people